Ranbaxy Laboratories gets AA+ rating for its proposed NCD from CARE

31 Aug 2012 Evaluate

Credit rating agency, CARE has assigned AA+ rating to Ranbaxy Laboratories’ long-term proposed Non Convertible Debentures (NCD) worth Rs 500 crore.

The company has received the said rating on the back of its dominant position in the domestic pharmaceutical market coupled with its established presence in the global market, which is further expected to strengthen, given its strong pipeline of Abbreviated New Drug Applications (ANDA), including First-to-file (FTF) applications.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1806.90
Dr. Reddys Lab 1272.95
Cipla 1512.10
Zydus Lifesciences 922.45
Lupin 2080.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×